JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin reiterated a Market Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $17 price target.
June 27, 2023 | 11:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities reiterated a Market Outperform rating on Sutro Biopharma (NASDAQ:STRO) and maintained a $17 price target.
The reiteration of the Market Outperform rating and maintenance of the $17 price target by JMP Securities analyst Reni Benjamin indicates a positive outlook for Sutro Biopharma's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100